Amplify Seymour Cannabis ETF

Curaleaf Holdings, Inc. released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 324.23 M (forecast USD 317.05 M), actual EPS USD 0.0895

Curaleaf reports Q1 gross profit of $157.3 million

Curaleaf Holdings Schedules Annual and Special Meeting

Curaleaf Holdings Fully Acquires Four 20 Pharma

Curaleaf Completes Acquisition of Four 20 Pharma to Strengthen European Market Position

Curaleaf Holdings, Inc. to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 317.05 M

Curaleaf Holdings, Inc. Launches $83 Million Stock Repurchase Program

Curaleaf Inc stock price gaps down, revenue exceeds expectations

Curaleaf Holdings, Inc. released FY2025 Annual Earnings on February 27 After-Market (EST), Actual Revenue: USD 1.268 B (Forecast: USD 1.274 B), Actual EPS: USD -0.3587

Curaleaf Holdings, Inc. released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 323.36 M (forecast USD 329.25 M), actual EPS USD -0.0904

Curaleaf Holdings, Inc. to Release FY2025 Q4 Earnings on February 26 After-Market EST, Forecast Revenue USD 328.27 M

Curaleaf Reports Strong Q4 Earnings and Plans to Exit Missouri Market

Curaleaf Holdings, Inc. released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 320.24 M (forecast USD 316.87 M), actual EPS USD -0.0838

Curaleaf Holdings, Inc. released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 944.77 M and EPS of USD -0.2695

Curaleaf Holdings, Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 317.11 M

Curaleaf Holdings, Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 314.52 M (forecast USD 313.92 M), actual EPS USD -0.0839

Curaleaf Holdings, Inc. released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 621.14 M and EPS of USD -0.1874

Curaleaf Holdings, Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 314.71 M

Curaleaf Holdings, Inc. released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 310.01 M (forecast USD 311.26 M), actual EPS USD -0.0998

Curaleaf Holdings, Inc. to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 314.07 M

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

TCNNF

TLRY

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Tilray Brands

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

Green Thumb Industries Inc.

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Curaleaf Holdings, Inc. has announced the replacement of its independent auditor PKF O’Connor Davies with BDO USA, effective May 6, 2026. This change follows an unqualified audit history, indicating it is a routine governance step rather than a response to any accounting issues. The transition is documented under Canadian continuous disclosure rules, emphasizing continuity in financial oversight. Analysts rate CURA stock as a Buy with a C$5.00 price target, while Spark's AI Analyst gives it a Neutral rating due to ongoing net losses and leverage concerns.

Tip Ranks

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings has opened two new medical dispensaries in Jacksonville Beach and Fernandina Beach, increasing its Florida locations to 73 and total nationwide stores to 165. CEO Boris Jordan stated that this expansion aligns with their strategy to enhance their presence in the medical cannabis market, allowing for better localized product offerings and patient-focused services across Florida.

fidelity

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

StockTitan

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

CRLBF

Companies selling recreational marijuana in Illinois and Connecticut are facing lawsuits for allegedly failing to warn consumers about health risks associated with the drug. The lawsuits, filed on May 4, claim that cannabis can lead to serious health issues, including addiction and mental health disorders. Plaintiffs seek damages and clearer product warnings. The defendants, including Cresco and Curaleaf, deny the allegations, asserting compliance with state laws and regulations. The lawsuits highlight concerns over the marketing of marijuana products without adequate risk disclosures.

ZeroHedge

Cresco Labs Inc.

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

CNBS

The AdvisorShares Pure US Cannabis ETF (MSOS) has seen a significant increase of 31% in one month and 69% over the past year, largely due to its holdings in US multi-state operators benefiting from potential Section 280E tax relief if cannabis rescheduling occurs. The Amplify Seymour Cannabis ETF (CNBS) provides diversified exposure to the US cannabis market.

Cannabis rescheduling could unlock the biggest MSO rally since 2021

Curaleaf Holdings, Inc. filed a Form 6-K with the SEC, reporting unaudited interim financials for Q1 2026. The filing includes financial statements as of March 31, 2026, and management's analysis, ensuring compliance and transparency. The latest analyst rating for CURA stock is a Buy with a C$5.50 price target, while Spark's AI Analyst rates it as Neutral, citing improving cash flow but weak underlying profitability. Curaleaf operates in the cannabis sector, registered with the SEC, and has a market cap of C$3.45B.

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

A series of federal lawsuits have been filed against major cannabis companies, including Cresco Labs and Curaleaf, accusing them of misleading consumers about the medicinal benefits of their products. The lawsuits allege that these companies marketed cannabis as a treatment for various conditions despite knowing the scientific evidence was weak or nonexistent. Concurrently, the European Food Safety Authority has stated it cannot confirm the safety of CBD, while the U.S. government plans to include these products in Medicare without FDA approval, raising significant concerns about public health and safety.

MorningStar

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

SHOP

The TSX Composite Index fell 71.06 points to 33,566.91, influenced by a drop in Shopify shares, which fell 15.6%. TMX Group reported better-than-expected earnings, while Dream Impact Trust's losses widened. Health-care stocks rose, with Curaleaf and Bausch Health gaining. The TSX Venture Exchange also declined. In the U.S., stocks surged, with the Dow up 356.63 points and the NASDAQ hitting an all-time high. Oil prices dropped, while gold prices increased significantly. Overall, 85% of S&P 500 companies exceeded earnings expectations.

Baystreet

Bausch Health

Shopify 

Kinross Gold

ZHONGJIN GOLD

EFUND GOLD MI-U

Abrdn Gold ETF Trust

VALUEGOLD ETF

Direxion Daily Jr Gold Miners Bull 2X

SPDR S&P Health Equip

Sprott GLD Miners Etf

Us Gbl GLD & Met

ALPS Medical Breakthrough

Abrdn Precious Metals Basket ETF Trust

Direxion Daily SHOP Bear 1X ETF

EFUND GOLD MI-R

iShares US Medical Devices

iShares MSCI Global Gold Miners

SPDR Gold Minishares

ChinaAMC Gold ETF

iShares Gold Trust

VanEck Junior Gold Miners ETF

GLOBAL X Gold Explorers

VanEck Gold Miners ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Roundhill Gold Miners Weeklypay ETF

EFUND GOLD MI ETF

TSX Staggers by Tuesday Finish

Curaleaf Holdings, Inc. reported its first quarter 2026 results, showcasing a net revenue of $324 million, a 6% increase year-over-year. The company achieved a gross profit margin of 49% and net income of $70 million. Curaleaf expanded its retail presence, opening new dispensaries in Florida and Maine, and launched new products. The company also completed the buyout of its German subsidiary, Four 20 Pharma, increasing its ownership to 100%. Curaleaf's CEO highlighted the positive shift in the cannabis industry due to recent regulatory changes, positioning the company for future growth.

16:01 ETCuraleaf Reports First Quarter 2026 Results: Robust Growth and Net Income

Amplify Seymour Cannabis ETF(CNBS.US)

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

Cannabis rescheduling could unlock the biggest MSO rally since 2021

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

TSX Staggers by Tuesday Finish

16:01 ETCuraleaf Reports First Quarter 2026 Results: Robust Growth and Net Income